Evidence map›Paper›PMID 38613804›Full record

ReviewAging2024

The mechanism of USP43 in the development of tumor: a literature review.

Ziqi Zhao, Meichen Liu, Zhikun Lin, Mengru Zhu, Linlin Lv, Xinqing Zhu, Rui Fan, Abdullah Al-Danakh, Hui He, Guang Tan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ziqi ZhaoDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
Meichen LiuDepartment of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
Zhikun LinDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
Mengru ZhuDepartment of Plastic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
Linlin LvDepartment of Pharmacy, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
Xinqing ZhuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
Rui FanInstitute of Cardiovascular Sciences and Key Laboratory of Molecular Cardiovascular Sciences, National, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Abdullah Al-DanakhDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
Hui HeDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
Guang TanDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian 116011, China.
First Affiliated Hospital of Dalian Medical University · CNDalian Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ubiquitination of the proteins is crucial for governing protein degradation and regulating fundamental cellular processes. Deubiquitinases (DUBs) have emerged as significant regulators of multiple pathways associated with cancer and other diseases, owing to their capacity to remove ubiquitin from target substrates and modulate signaling. Consequently, they represent potential therapeutic targets for cancer and other life-threatening conditions. USP43 belongs to the DUBs family involved in cancer development and progression. This review aims to provide a comprehensive overview of the existing scientific evidence implicating USP43 in cancer development. Additionally, it will investigate potential small-molecule inhibitors that target DUBs that may have the capability to function as anti-cancer medicines.

Indexed as

NeoplasmsAnimalsAntineoplastic AgentsDeubiquitinating EnzymesEndopeptidasesHumansSignal TransductionUbiquitinationAntineoplastic AgentsDeubiquitinating EnzymesEndopeptidasescancerdeubiquitinasetumor immune microenvironmentUSP43

Identifiers

PMID38613804
PMCPMC11042928
OpenAlexW4394579381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.